Loading
Ripretinib kept fourth-line GIST under control six times longer than placebo and improved survival.
INVICTUS, trial NCT03353753 sponsored by Deciphera and published in Lancet Oncology in 2020, showed that the switch-control kinase inhibitor ripretinib keeps fourth-line gastrointestinal stromal tumour under control roughly six times longer than placebo and improves survival. It randomised 129 patients after at least three kinase inhibitors and met its primary progression-free survival endpoint with a very large effect and a survival benefit, leading to approval in May 2020. OnCo links it to sarcomas and GIST, KIT as a target and ripretinib. Whether ripretinib can move earlier in the sequence, which INTRIGUE and the mutation-selected INSIGHT trial address, is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
129 enrolled.
Shares Ripretinib, Deciphera Pharmaceuticals (Ono), Imatinib-resistant GIST, Small-molecule kinase inhibitors.
Shares Ripretinib, Deciphera Pharmaceuticals (Ono), Imatinib-resistant GIST, KIT.
Shares Ripretinib, KIT, Sarcomas (soft tissue, bone, GIST).
Shares Deciphera Pharmaceuticals (Ono), Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors.
Shares Ripretinib, Imatinib-resistant GIST.
Shares KIT, Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors.
Shares Imatinib-resistant GIST, Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors.